APG Asset Management N.V. Buys 22,349 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

APG Asset Management N.V. boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 288.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,104 shares of the medical research company's stock after purchasing an additional 22,349 shares during the quarter. APG Asset Management N.V. owned 0.06% of Charles River Laboratories International worth $5,367,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at approximately $601,000. JPMorgan Chase & Co. lifted its stake in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after purchasing an additional 85,759 shares during the last quarter. Veracity Capital LLC acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth approximately $589,000. Lord Abbett & CO. LLC boosted its holdings in shares of Charles River Laboratories International by 5.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company's stock worth $21,413,000 after buying an additional 5,959 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after acquiring an additional 47,221 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the company's stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of recent research reports. Morgan Stanley decreased their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their target price for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a research note on Monday, March 3rd. Mizuho reduced their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. Finally, UBS Group reissued a "neutral" rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $182.00.

Charles River Laboratories International Stock Down 0.3 %

Shares of NYSE CRL traded down $0.29 during trading on Thursday, reaching $103.96. The company had a trading volume of 453,739 shares, compared to its average volume of 885,082. The business's 50-day moving average is $153.13 and its 200 day moving average is $175.23. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a market cap of $5.11 billion, a PE ratio of 693.11, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.46 EPS. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).